UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(
201 E Kennedy Blvd, Suite 700 Tampa, FL, 33602
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: Common Stock
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers;
On March 26, 2024, Innoveren Scientific, Inc. (the “Company”) issued to certain executive officers an aggregate of 186,048 shares of common stock in lieu of accrued salary at a rate of $0.25 per share for amounts owed and an aggregate of 213,952 shares for payment of directors’ fees owed. In addition, the Company issued its officers and directors an aggregate of 400,000 options to purchase common stock at $0.03 per share which was above the closing price of the Company’s common stock on March 25, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Innoveren Scientific, Inc. | ||
| Date: April 1, 2024 | By: | /s/ Jeremy Daniel |
| Jeremy Daniel | ||
| Chief Financial Officer | ||
Cover |
Apr. 01, 2024 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Apr. 01, 2024 |
| Entity File Number | 001-36763 |
| Entity Registrant Name | Innoveren Scientific, Inc. |
| Entity Central Index Key | 0001591165 |
| Entity Tax Identification Number | 46-3312262 |
| Entity Incorporation, State or Country Code | NV |
| Entity Address, Address Line One | 151 W4th St. |
| Entity Address, Address Line Two | Ste 223 |
| Entity Address, City or Town | Cincinnati |
| Entity Address, State or Province | OH |
| Entity Address, Postal Zip Code | 45202 |
| City Area Code | 844 |
| Local Phone Number | 633-6839 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | false |